ArticleFrontiers in immunology2026

Novel B-Cell targeting therapy with subcutaneous ofatumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.

Xuetao Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.